Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1191 Monotherapy and Combination with Durvalumab in Advanced Solid Tumors
NCT03946800Phase 1Completed
- Sponsor
- MedImmune
- Start
- May 2019
- Primary completion
- Aug 2023
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of MEDI1191 in solid tumor (advanced stage) (3 arms), sponsored by MedImmune. Primary endpoints: Adverse Events, Serious Adverse Events, and Dose Limiting Toxicities and Objective Response Rate at 3.5 years. Started May 2019; status: completed.
02
Drugs
MEDI1191
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03946800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946800.